Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Dan Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6661-2961; OpenAlex author ID A5012808034. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. [Expression of Concern] ETS‑1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer. First author DOI 10.3892/ijo.2025.5786↗
  2. Dickkopf-related protein 3 alters aerobic glycolysis in pancreatic cancer BxPC-3 cells, promoting CD4+ T-cell activation and function. Last author DOI 10.1186/s40001-021-00567-x↗
  3. ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer. First author DOI 10.3892/ijo.2016.3770↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhang Xiu · 2 shared papers, 2017–2025 · strength 0.39
  2. Cailian Wang · 2 shared papers, 2017–2025 · strength 0.39
  3. Qingqu Guo · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.